CORONA Remedies Limited (CORONA) has announced its unaudited financial results for the quarter and half year ended September 30, 2026, delivering the highest ever revenue with a growth of 22% year-on-year (Y-o-Y) basis. This impressive performance marks a significant milestone for the company, which continues to be one of the fastest growing companies among the top 30 Indian pharmaceutical companies.

Financial Performance

The financial performance snapshot reveals robust growth across key metrics. Revenue from operations stood at ₹441.2 crore for Q2FY27, a 22.2% increase compared to ₹361.1 crore in Q2FY26. EBITDA rose to ₹96.0 crore, up 22.3% from ₹78.5 crore in the same quarter last year. Profit After Tax (PAT) increased to ₹60.3 crore, reflecting a 15.3% growth from ₹52.3 crore in Q2FY26.

Key Business Highlights

CORONA Remedies Limited has demonstrated operational excellence and disciplined execution, leveraging all growth drivers to outperform the Indian Pharmaceutical Market (IPM). The company has now outpaced the IPM growth by 1.9 times as per MAT Sep’26. Additionally, CORONA has received Good Manufacturing Practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its manufacturing facility at Bhayla, Ahmedabad.

Commenting on the results, Mr. Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said: “We are pleased to announce another quarter of strong, consistent growth. This outperformance reflects our disciplined execution and consistent focus on our long-term strategy. We remain committed to strengthening our core therapies, building powerful brands, driving operational excellence, and investing in capabilities that will support our future growth.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of CORONA Remedies Limited

CORONA Remedies Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

CORONA holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 2.07 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The business compounds revenue at 16.6% and profits at 29.7% CAGR. That is strong double-digit growth on both counts. Buyers show up with 2.0x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. The business grows revenue at 16.6% and profits at 29.7%, with D/E of 0.14. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.07 premium is usually justified. Check Fundamentals of CORONA Remedies Limited.

Sanofi India Limited’s board meeting commenced at 2:30 p.m. and concluded at 4:45 p.m. on October 29, 2026. The meeting focused on strategic initiatives and operational updates, underscoring the company’s commitment to innovation and growth in the pharmaceutical sector.

Strategic Initiatives

The board deliberated on several strategic initiatives aimed at expanding market reach and enhancing product portfolios. Notably, the meeting highlighted plans to strengthen partnerships in the cardiovascular and diabetes segments, which are pivotal to the company’s growth strategy.

Operational Updates

The meeting also provided updates on operational efficiencies and cost management. The board reviewed measures taken to improve gross margins and operational efficiencies, which have contributed to the company’s robust financial performance.

Future Outlook

As a result of these strategic discussions and operational reviews, Sanofi India Limited is poised to continue its momentum in the pharmaceutical industry, focusing on sustainable long-term value creation and market leadership.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sanofi India Limited

Sanofi India Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Sanofi falls 13.8% over three months and has not found a floor yet. D/E of 0.00 and a 4.16% dividend yield give the balance sheet a decent cushion. The 4.16% dividend yield is about the only thing keeping income investors interested right now. The stock sits at 2% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at -12.6% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Sanofi India Limited.

Senores Pharmaceuticals Limited (SENORES) announced its unaudited financial results for the quarter and half year ended 30th September 2026, showcasing robust financial and operational performance. The company reported a 25% year-on-year increase in revenue for Q2 FY27 and a 38% rise in EBITDA, marking consistent strong growth across its businesses.

Segmental Highlights

The company’s revenue for Q2 and H1 FY27 grew by 25% and 30% respectively on a year-on-year basis. Notably, the Regulated Markets segment saw a 34% increase in revenue, while the Emerging Markets segment grew by 21% in Q2 and 25% in H1 FY27. The company’s portfolio in Regulated Markets nearly doubled, expanding from 34 ANDAs as of September 2025 to 64 ANDAs as of September 2026, with 23 commercialized products.

Operational Excellence

Despite initial set-up and operating costs associated with Zoraya and Amerisyn, EBITDA for Q2 and H1 FY27 grew by 38% and 58% respectively, with margin expansion of approximately 290 bps and 530 bps on a year-on-year basis. The company’s cash from operations stood at ₹38 crores in H1 FY27, reflecting a consistent improvement in cash flow generation.

Forward-Looking Outlook

Senores Pharmaceuticals Limited remains optimistic about its future growth trajectory, on track to deliver 30-40% revenue growth and 50-60% PAT growth in FY27. The company’s robust product pipeline, expanded manufacturing capabilities, and strong commercial launch visibility underpin its positive outlook for the year and beyond.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Senores holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.33 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Revenue grows at 159.1% and profits at 139.2% CAGR. Both numbers are exceptional. The stock holds at 69% of its 52-week range with RSI at 44. In other words, neither side has a clear edge right now. Both the business and the stock move in the right direction. Revenue grows at 159.1%, profits at 139.2%, and the PEG sits at 0.33 — below its growth rate. That combination is rare. Check Fundamentals of Senores Pharmaceuticals Limited.